but with less risk of bioprosthetic valve dysfunction, in patients with small annuli and symptomatic severe aortic stenosis. Presenting the data here at CRT 2025, SMART lead Investigator Howard ...
Hosted on MSN23d
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the Small Annuli Randomized To Evolut or SAPIEN ... a small annulus can benefit from Evolut's differentiated valve design." AS is stated to be a widespread valvular heart ...
Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...
Medtronic : Data Confirms Superior Valve Performance Of Evolut TAVR System In Small Annulus Patients
(RTTNews) - Medtronic plc (MDT) released the two-year results of the SMall Annuli Randomized ... disabling stroke, and heart failure hospitalization, and continued superior valve performance ...
DurAVR ® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm 2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler ...
Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN ... trial of transfemoral transcatheter aortic valve replacement ("TAVR"), conducted in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback